Page last updated: 2024-08-26

sr141716 and Innate Inflammatory Response

sr141716 has been researched along with Innate Inflammatory Response in 49 studies

Research

Studies (49)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	23 (46.94)	29.6817
2010's	25 (51.02)	24.3611
2020's	1 (2.04)	2.80

Authors

Authors	Studies
Borea, PA; Brogi, S; Corelli, F; Di Marzo, V; Falciani, C; Guida, F; Ligresti, A; Luongo, L; Maione, S; Mugnaini, C; Pasquini, S; Pedani, V; Pesco, N; Tafi, A; Varani, K	1
Baier, A; Christ, B; Churin, Y; Dierkes, C; Glebe, D; Helmrich, N; Herebian, D; Irungbam, K; Mayatepek, E; Ocker, M; Roderfeld, M; Roeb, E; Windhorst, A	1
Kang, Y; Kim, D; Lee, GJ; Lee, JY; Lee, PR; Oh, SB; Won, CH	1
Chitrala, KN; Enos, RT; Ganewatta, MS; McCellan, J; Mehrpouya-Bahrami, P; Murphy, EA; Nagarkatti, M; Nagarkatti, P; Tang, C; Velazquez, KT	1
Choi, CS; Han, JH; Kim, IY; Kim, JE; Kim, KW; Kim, W; Lee, EK; Lee, YJ; Park, JH; Rho, JG; Seong, JK; Shin, H; Son, DH; Song, BJ; Yoon, J; Yoon, SG	1
Bae, SH; Chang, E; Kim, DH; Lee, DH; Park, CY; Yang, H	1
de La Serre, CB; Grunewald, ZI; Kirkland, R; Lee, S; Ross, M	1
Han, JH; Kim, KW; Kim, W; Park, JY; Rho, JG; Seong, JK; Shin, H; Son, DH; Yoon, SH	1
Asare-Bediako, I; Bergman, RN; Clegg, DJ; Iyer, MS; Kabir, M; Kim, SP; Kolka, CM; Paszkiewicz, RL; Richey, JM; Stefanovski, D; Woolcott, OO; Wu, Q	1
Aveta, T; Borrelli, F; Buono, L; Capasso, R; Di Marzo, V; Izzo, AA; Orlando, P; Pagano, E	1
Dopart, R; Kendall, DA; Lu, D	1
Atkin, SL; Coady, AM; Javed, Z; Kilpatrick, ES; Sathyapalan, T	1
Atkinson, RD; DeLeve, LD; Kanel, GC; McCuskey, RS; Wang, X	1
Bono, F; Desitter, P; Dol-Gleizes, F; Gilde, A; Hennuyer, N; Marés, AM; Paumelle, R; Schaeffer, P; Staels, B; Visentin, V	1
Burgos, E; Goicoechea, C; Martín, MI; Pascual, D	1
Shwarts, V	1
Abe, T; Fukuda, H; Yoshihara, S	1
Biemer-Daub, G; Herling, AW; Miranville, A; Voss, MD	1
Baek, HS; Jin, HY; Liu, WJ; Park, JH; Park, TS	1
Lotersztajn, S; Mallat, A	1
Diane, A; Kelly, SE; Mangat, R; Novak, S; Proctor, SD; Russell, JC; Vine, DF; Wang, Y	1
Bátkai, S; Gao, B; Harvey-White, J; Haskó, G; Mackie, K; Mukhopadhyay, B; Mukhopadhyay, P; Pacher, P; Pan, H; Patel, V; Rajesh, M	1
DeLong, GT; Lichtman, AH; Poklis, A; Wolf, CE	1
Ballantyne, CM; Mansoori, A; Perrard, JL; Perrard, XD; Smith, CW; Wang, Q; Wu, H	1
Aouad, L; Bell-Anderson, KS; Caterson, ID; Farrell, GC; Larter, CZ; Phuyal, J; Sanz, FR; Williams, H	1
Bennetzen, MF	1
Alhouayek, M; Cani, PD; Delzenne, NM; Lambert, DM; Muccioli, GG	1
Acharya, A; Balaraman, R; Chatterjee, A; Jain, MR; Mohapatra, J; Pandya, G; Sharma, M	1
Agaimy, A; Brenneisen, R; Millonig, G; Mueller, S; Ocker, M; Patsenker, E; Schneider, V; Seitz, HK; Stickel, F; Stoll, M; Wissniowski, T	1
Hohmann, AG; Nackley, AG; Suplita, RL	1
Hohmann, AG; Makriyannis, A; Nackley, AG	1
Chapman, V; Jhaveri, MD; Kelly, S; Kendall, DA; Sagar, DR	1
Colleoni, M; Costa, B; Franke, C; Giagnoni, G; Trovato, AE	1
Hohmann, AG; Makriyannis, A; Nackley, AG; Zvonok, AM	1
Chapman, V; Elmes, SJ; Jhaveri, MD; Kendall, DA; Smart, D	1
Breuer, A; Fride, E; Hanus, L; Ponde, D	1
Guaza, C; Molina-Holgado, E; Ortega-Gutiérrez, S	1
Marx, J	1
Behn, A; Ur, E	1
Bueno, L; Fioramonti, J; Sanson, M	1
Connell, JM; Ritchie, SA	1
Costa, B	1
Croci, T; Zarini, E	1
Arnone, M; Bensaid, M; Chabbert, M; Croci, T; Cruccioli, N; Elachouri, G; Gallas, JF; Gary-Bobo, M; Herbert, JM; Janiak, P; Lacheretz, F; Le Fur, G; Maffrand, JP; Marini, P; Oury-Donat, F; Pfersdorff, C; Ravinet-Trillou, C; Roque, C; Scatton, B; Soubrié, P	1
Bettoni, I; Colleoni, M; Comelli, F; Costa, B; Giagnoni, G	1
Bernardini, D; Colavito, D; D'Arrigo, A; Dalle Carbonare, M; Dam, M; Del Giudice, E; Fabris, M; Leon, A; Stecca, A	1
Aronne, LJ; Isoldi, KK	1
Chapman, V; Drew, LJ; Harris, J	1
Capasso, F; Capasso, R; Di Marzo, V; Fezza, F; Izzo, AA; Mascolo, N; Pinto, A	1

Reviews

6 review(s) available for sr141716 and Innate Inflammatory Response

Article	Year
[Adipose tissue inflammation and atherosclerosis]. Kardiologiia, 2009, Volume: 49, Issue:12 Topics: Adipokines; Adipose Tissue; Atherosclerosis; Chemotaxis; Cytokines; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Macrophages; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant; Vasoconstrictor Agents	2009
Endocannabinoids and their role in fatty liver disease. Digestive diseases (Basel, Switzerland), 2010, Volume: 28, Issue:1 Topics: Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Fatty Liver; Humans; Hypertension, Portal; Inflammation; Insulin Resistance; Liver Cirrhosis; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant	2010
Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options. Danish medical bulletin, 2011, Volume: 58, Issue:4 Topics: Adiponectin; Adipose Tissue; Animals; Body Mass Index; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Case-Control Studies; Endocannabinoids; Fatty Acids, Nonesterified; Feeding Behavior; Female; Genetic Variation; Humans; Inflammation; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Reference Values; Rimonabant; Risk Factors; Weight Loss	2011
The obesity epidemic and its cardiovascular consequences. Current opinion in cardiology, 2006, Volume: 21, Issue:4 Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Lactones; Life Style; Lipid Metabolism; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Waist-Hip Ratio	2006
The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2007, Volume: 17, Issue:4 Topics: Cardiovascular Diseases; Fatty Acids, Nonesterified; Humans; Inflammation; Insulin Resistance; Interleukin-6; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Tumor Necrosis Factor-alpha	2007
Overweight and obesity: key components of cardiometabolic risk. Clinical cornerstone, 2007, Volume: 8, Issue:3 Topics: Adipocytes; Adipokines; Cardiovascular Diseases; Humans; Inflammation; Life Style; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; United States	2007

Trials

1 trial(s) available for sr141716 and Innate Inflammatory Response

Article	Year
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome. Clinical endocrinology, 2017, Volume: 86, Issue:3 Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammation; Interleukin-8; Metformin; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Vascular Endothelial Growth Factor A; Weight Loss	2017

Article

Year

Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.

Clinical endocrinology, 2017, Volume: 86, Issue:3

Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammation; Interleukin-8; Metformin; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Vascular Endothelial Growth Factor A; Weight Loss

2017

Other Studies

42 other study(ies) available for sr141716 and Innate Inflammatory Response

Article	Year
Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists. Journal of medicinal chemistry, 2012, Jun-14, Volume: 55, Issue:11 Topics: Amides; Animals; CHO Cells; Combinatorial Chemistry Techniques; Cricetinae; Cricetulus; Cyclic AMP; Drug Design; Drug Inverse Agonism; HEK293 Cells; Humans; Immunologic Factors; Indoles; Inflammation; Mice; Models, Molecular; Pain; Pain Measurement; Radioligand Assay; Receptor, Cannabinoid, CB2; Structure-Activity Relationship	2012
Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4 Cellular and molecular gastroenterology and hepatology, 2022, Volume: 13, Issue:4 Topics: Animals; Carcinogenesis; Cholestasis; Inflammation; Male; Mice; Receptor, Cannabinoid, CB1; Rimonabant	2022
The analgesic effect of refeeding on acute and chronic inflammatory pain. Scientific reports, 2019, 11-14, Volume: 9, Issue:1 Topics: Acute Pain; Analgesics, Opioid; Animals; Chronic Pain; Disease Models, Animal; Eating; Food Deprivation; Formaldehyde; Freund's Adjuvant; Glucose; Hot Temperature; Hyperalgesia; Inflammation; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Naloxone; Narcotic Antagonists; Pain Management; Pain Measurement; Rimonabant	2019
Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Scientific reports, 2017, 11-15, Volume: 7, Issue:1 Topics: Adipose Tissue; Animals; Cannabinoid Receptor Antagonists; Cell Movement; Cytokines; Gastrointestinal Microbiome; Inflammation; Macrophages; Male; Mice; Obesity; Receptor, Cannabinoid, CB1; Rimonabant	2017
Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:9 Topics: Adipose Tissue; Animals; Brain; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Experimental; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Obese; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; Rimonabant	2018
CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes. PloS one, 2018, Volume: 13, Issue:10 Topics: Adenylate Kinase; Animals; Diabetes Mellitus, Experimental; Fatty Liver; Inflammation; Liver; NF-E2-Related Factor 2; Obesity; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant; Severity of Illness Index; Signal Transduction	2018
Cannabinoid receptor type-1 partially mediates metabolic endotoxemia-induced inflammation and insulin resistance. Physiology & behavior, 2019, 02-01, Volume: 199 Topics: Animals; Body Weight; Cannabinoid Receptor Antagonists; Eating; Endotoxemia; Inflammation; Insulin Resistance; Lipopolysaccharides; Liver; Male; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction	2019
A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:3 Topics: 3T3 Cells; Adipose Tissue; Animals; CHO Cells; Cricetulus; Cytokines; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Humans; Hypoglycemic Agents; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; RAW 264.7 Cells; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Weight Loss	2019
Activation of NPRs and UCP1-independent pathway following CB1R antagonist treatment is associated with adipose tissue beiging in fat-fed male dogs. American journal of physiology. Endocrinology and metabolism, 2019, 09-01, Volume: 317, Issue:3 Topics: Adipose Tissue; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Diet, High-Fat; Dogs; Gene Expression; Inflammation; Insulin Resistance; Male; Organelle Biogenesis; Receptor, Cannabinoid, CB1; Receptors, Adrenergic, beta; Receptors, Atrial Natriuretic Factor; Rimonabant; Thermogenesis; Uncoupling Protein 1; Weight Loss	2019
Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels. British journal of pharmacology, 2014, Volume: 171, Issue:17 Topics: Amides; Animals; Colitis; Disease Models, Animal; Ethanolamines; Gastrointestinal Motility; Inflammation; Injections, Intraperitoneal; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred ICR; Mustard Plant; Palmitic Acids; Piperidines; Plant Oils; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; TRPV Cation Channels	2014
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes. Cell stress & chaperones, 2016, Volume: 21, Issue:1 Topics: Animals; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Down-Regulation; Drug Inverse Agonism; Eating; Endocannabinoids; Endoplasmic Reticulum Stress; Humans; Inflammation; Insulin Resistance; Mitochondria; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction	2016
Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. The American journal of pathology, 2008, Volume: 173, Issue:4 Topics: Actins; Animals; Apolipoprotein A-I; Body Weight; Cells, Cultured; Diet; Disease Models, Animal; Fatty Liver; Hepatocytes; Inflammation; Liver; Liver Cirrhosis; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Organ Size; Piperidines; Pyrazoles; Rimonabant	2008
Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:1 Topics: Animals; Atherosclerosis; Cannabinoids; Chemokine CCL2; Cholesterol; Cytokines; Energy Intake; Female; Inflammation; Interleukin-12; Mice; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, LDL; Rimonabant	2009
Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests. European journal of pain (London, England), 2010, Volume: 14, Issue:1 Topics: Analgesics; Analgesics, Opioid; Anesthetics, Dissociative; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Benzoxazines; Camphanes; Facial Pain; Formaldehyde; Indomethacin; Inflammation; Ketamine; Male; Morphine; Morpholines; Motor Activity; Naphthalenes; Pain; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Temporomandibular Joint Disorders	2010
The cannabinoid receptor agonist WIN 55,212-2 inhibits antigen-induced plasma extravasation in guinea pig airways. International archives of allergy and immunology, 2010, Volume: 152, Issue:3 Topics: Animals; Antigens; Benzoxazines; Camphanes; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Capillary Permeability; Dipeptides; Evans Blue; Extravasation of Diagnostic and Therapeutic Materials; Guinea Pigs; Immunization; Indoles; Inflammation; Male; Morpholines; Naphthalenes; Neurokinin-1 Receptor Antagonists; Ovalbumin; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Respiratory Hypersensitivity; Rimonabant; Trachea	2010
Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages. Obesity (Silver Spring, Md.), 2010, Volume: 18, Issue:12 Topics: Adipocytes; Adipose Tissue; Animals; Anti-Obesity Agents; Blood Glucose; Cell Line; Culture Media, Conditioned; Diabetes Mellitus, Experimental; Dietary Fats; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Interleukin-10; Lipopolysaccharides; Macrophages; Male; Mice; Obesity; Phosphorylation; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Tumor Necrosis Factor-alpha	2010
Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat. European journal of pharmacology, 2010, Jul-10, Volume: 637, Issue:1-3 Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Glucose Tolerance Test; Immunohistochemistry; Inflammation; Male; Neurons; Peripheral Nerves; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Skin; Streptozocin; Time Factors; Tumor Necrosis Factor-alpha	2010
Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 299, Issue:2 Topics: Animals; Biomarkers; Blood Vessels; Body Weight; Cannabinoid Receptor Antagonists; Disease Models, Animal; Eating; Inflammation; Insulin Resistance; Intestinal Mucosa; Kidney Diseases; Kidney Glomerulus; Lipid Metabolism; Male; Metabolic Syndrome; Myocardial Ischemia; Piperidines; Prediabetic State; Pyrazoles; Rats; Rats, Mutant Strains; Renal Circulation; Rimonabant; Sclerosis; Thrombosis	2010
CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. British journal of pharmacology, 2010, Volume: 160, Issue:3 Topics: Animals; Arachidonic Acids; Cell Death; Cisplatin; Disease Models, Animal; Endocannabinoids; Glycerides; Inflammation; Kidney; Male; Mice; Mice, Knockout; Morpholines; Nephritis; Oxidative Stress; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction	2010
Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. Drug and alcohol dependence, 2010, Nov-01, Volume: 112, Issue:1-2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Cannabinoids; Cannabis; Catalepsy; Dose-Response Relationship, Drug; Dronabinol; Hallucinogens; Hypothermia; Inflammation; Male; Mice; Mice, Inbred ICR; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant	2010
Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:3 Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Chemokine CCL2; Diet; Dietary Fats; Disease Models, Animal; Energy Intake; Inflammation; Liver; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Gain; Weight Loss	2011
Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. International journal of obesity (2005), 2011, Volume: 35, Issue:12 Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose Intolerance; Glucose Tolerance Test; Inflammation; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2011
Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011, Volume: 25, Issue:8 Topics: Animals; Arachidonic Acids; Benzodioxoles; Colitis; Disease Models, Animal; Endocannabinoids; Endotoxemia; Enzyme Inhibitors; Glycerides; Humans; Indoles; Inflammation; Inflammation Mediators; Inflammatory Bowel Diseases; Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Trinitrobenzenesulfonic Acid	2011
Retinol-binding protein 4 : a possible role in cardiovascular complications. British journal of pharmacology, 2011, Volume: 164, Issue:8 Topics: 3T3-L1 Cells; Adipokines; Animals; Apolipoprotein E3; Atherosclerosis; Base Sequence; Cardiovascular Diseases; Cholesterol; DNA Primers; Female; Gene Expression Regulation; Hypercholesterolemia; Inflammation; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Real-Time Polymerase Chain Reaction; Retinol-Binding Proteins, Plasma; Rimonabant	2011
Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Molecular medicine (Cambridge, Mass.), 2011, Volume: 17, Issue:11-12 Topics: Acetaldehyde; Animals; Apoptosis; Cannabinoids; Cell Hypoxia; Cell Proliferation; Collagen; Female; Hepatic Stellate Cells; Humans; Hydrogen Peroxide; Inflammation; Liver; Liver Cirrhosis, Alcoholic; Male; Matrix Metalloproteinases; Mice; Middle Aged; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; RNA, Messenger; Up-Regulation	2011
A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience, 2003, Volume: 117, Issue:3 Topics: Analgesics; Animals; Behavior, Animal; Benzoxazines; Camphanes; Cannabinoids; Carrageenan; Disease Models, Animal; Drug Administration Routes; Drug Interactions; Edema; Functional Laterality; Gene Expression Regulation; Immunohistochemistry; Inflammation; Male; Mechanoreceptors; Morpholines; Naphthalenes; Pain; Pain Measurement; Physical Stimulation; Piperidines; Proto-Oncogene Proteins c-fos; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Spinal Cord; Time Factors	2003
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience, 2003, Volume: 119, Issue:3 Topics: Analgesics; Animals; Camphanes; Cannabinoids; Carrageenan; Disease Models, Animal; Drug Interactions; Hyperalgesia; Inflammation; Male; Nociceptors; Pain; Pain Threshold; Piperidines; Posterior Horn Cells; Proto-Oncogene Proteins c-fos; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Rimonabant	2003
Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. The European journal of neuroscience, 2003, Volume: 18, Issue:8 Topics: Animals; Arachidonic Acids; Carrageenan; Diterpenes; Dose-Response Relationship, Drug; Drug Interactions; Evoked Potentials; Hindlimb; Inflammation; Male; Neural Inhibition; Physical Stimulation; Piperidines; Posterior Horn Cells; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Drug; Rimonabant; Spinal Cord; Time Factors	2003
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. British journal of pharmacology, 2004, Volume: 143, Issue:2 Topics: Administration, Oral; Animals; Camphanes; Cannabidiol; Capsaicin; Carrageenan; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hyperalgesia; Inflammation; Italy; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Drug; Rimonabant; Time Factors	2004
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. Journal of neurophysiology, 2004, Volume: 92, Issue:6 Topics: Analgesics; Animals; Camphanes; Cannabinoids; Carrageenan; Edema; Electric Stimulation; Inflammation; Male; Nerve Fibers, Unmyelinated; Nociceptors; Piperidines; Posterior Horn Cells; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Rimonabant	2004
Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. The European journal of neuroscience, 2004, Volume: 20, Issue:9 Topics: Action Potentials; Animals; Camphanes; Cannabinoids; Carrageenan; Disease Models, Animal; Inflammation; Ligation; Male; Neural Inhibition; Neuralgia; Nociceptors; Peripheral Nervous System Diseases; Physical Stimulation; Piperidines; Posterior Horn Cells; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Sensory Receptor Cells; Spinal Nerves	2004
Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. Neuropharmacology, 2005, Volume: 48, Issue:8 Topics: Animals; Binding, Competitive; Body Temperature; Camphanes; Cannabidiol; Capsaicin; Drug Interactions; Ear, External; Gastrointestinal Motility; Inflammation; Mice; Mice, Inbred ICR; Mice, Inbred Strains; Motor Activity; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant	2005
Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia, 2005, Nov-01, Volume: 52, Issue:2 Topics: Animals; Arachidonic Acids; Astrocytes; Cells, Cultured; Cytokines; Endocannabinoids; Furans; Inflammation; Lipopolysaccharides; Nitric Oxide; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant	2005
Drug development. Drugs inspired by a drug. Science (New York, N.Y.), 2006, Jan-20, Volume: 311, Issue:5759 Topics: Animals; Anti-Obesity Agents; Anxiety; Arachidonic Acids; Blood Pressure; Brain; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Endocannabinoids; Humans; Inflammation; Neurons; Obesity; Osteoporosis; Pain; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Smoking Cessation	2006
Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterology and motility, 2006, Volume: 18, Issue:10 Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Colitis; Colon; Dose-Response Relationship, Drug; Indoles; Inflammation; Male; Manometry; Morpholines; Muscle Contraction; Muscle, Smooth; Naphthalenes; Nociceptors; Pain; Piperidines; Pressure; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Rimonabant; Trinitrobenzenesulfonic Acid	2006
Rimonabant: more than an anti-obesity drug? British journal of pharmacology, 2007, Volume: 150, Issue:5 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Arthritis; Humans; Hyperalgesia; Inflammation; Obesity; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2007
Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. British journal of pharmacology, 2007, Volume: 150, Issue:5 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Arthritis, Experimental; Body Weight; Edema; Female; Freund's Adjuvant; Hot Temperature; Hyperalgesia; Inflammation; Joints; Nitric Oxide; Obesity; Pain Measurement; Pain Threshold; Piperidines; Pyrazoles; Rats; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Touch	2007
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:1 Topics: Animals; Cannabinoid Receptor Antagonists; Fatty Liver; Inflammation; Liver; Male; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA; Tumor Necrosis Factor-alpha	2007
The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. British journal of pharmacology, 2007, Volume: 152, Issue:5 Topics: Acute Disease; Animals; Biphenyl Compounds; Body Temperature; Camphanes; Carrageenan; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Hindlimb; Hyperalgesia; Inflammation; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Pain; Pain Measurement; Pain Threshold; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant	2007
A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story... Journal of neuroendocrinology, 2008, Volume: 20 Suppl 1 Topics: Amides; Animals; Anti-Inflammatory Agents; Benzoxazines; Body Temperature; Camphanes; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Ear Auricle; Edema; Endocannabinoids; Ethanolamines; Fatty Acids; Female; Inflammation; Mice; Mice, Inbred BALB C; Morpholines; Naphthalenes; Palmitic Acids; Passive Cutaneous Anaphylaxis; Piperidines; Pyrazoles; Rimonabant; Stearic Acids; Time Factors	2008
Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport, 2000, Aug-21, Volume: 11, Issue:12 Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Carrageenan; Electric Stimulation; Endocannabinoids; Hindlimb; Inflammation; Injections, Spinal; Nociceptors; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Reference Values; Rimonabant; Synaptic Transmission	2000
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. British journal of pharmacology, 2001, Volume: 134, Issue:5 Topics: Adrenergic alpha-Antagonists; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Croton Oil; Dose-Response Relationship, Drug; Endocannabinoids; Enzyme Inhibitors; Ethanolamines; Gastrointestinal Motility; Gastrointestinal Transit; Hexamethonium; Inflammation; Intestine, Small; Male; Mice; Mice, Inbred ICR; Naloxone; NG-Nitroarginine Methyl Ester; Nicotinic Antagonists; Nitric Oxide Synthase; Palmitic Acids; Phenylmethylsulfonyl Fluoride; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Yohimbine	2001